Mylan Pharmaceuticals, Inc., et al. v. Warner Chilcott Public Limited Company, et al.

Citation Number: 12-3824
Brief of the Federal Trade Commission as amicus curiae before the United States District Court for the Eastern District of Pennsylvania, addressing the question of whether reformulations of a branded company’s products that offer patients little or no therapeutic advantages – also known as “product-switching” or “product-hopping” – obstructs meaningful competition by generic drug companies and thus, constitutes exclusionary conduct.